| Host |
Monospecific Mouse |
| Klon |
ZM186 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Prostate. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Recombinant human Cytokeratin 5 (KRT5) protein fragment (around aa 318-491) |
| Lokalisation |
Cytoplasm |
Cytokeratin 5
|
Zeta Corporation |
ZM186 |
1 ml |
Concentrate |
CE/IVD |
Z2505ML |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM186 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Prostate. |
| Verdünnung |
- |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Recombinant human Cytokeratin 5 (KRT5) protein fragment (around aa 318-491) |
| Lokalisation |
Cytoplasm |
Cytokeratin 5
|
Zeta Corporation |
ZM186 |
7 ml |
Ready-to-use |
CE/IVD |
Z2505MP |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM186 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Prostate. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Recombinant human Cytokeratin 5 (KRT5) protein fragment (around aa 318-491) |
| Lokalisation |
Cytoplasm |
Cytokeratin 5
|
Zeta Corporation |
ZM186 |
0.5 ml |
Concentrate |
CE/IVD |
Z2505MS |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM186 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Prostate. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Recombinant human Cytokeratin 5 (KRT5) protein fragment (around aa 318-491) |
| Lokalisation |
Cytoplasm |
Cytokeratin 5
|
Zeta Corporation |
ZM186 |
0.1 ml |
Concentrate |
CE/IVD |
Z2505MT |
-
|
| Host |
Mouse |
| Klon |
XM26 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Reveal modified Citrate pH 6.0 |
| Positivkontrolle |
Normal prostate |
| Verdünnung |
1:25 |
| Isotyp |
Mouse IgG1 kappa |
| Lokalisation |
Cytoplasmic |
Cytokeratin 5 (CK5)
|
Biocare Medical |
XM26 |
0.1 ml |
Concentrate |
CE/IVD |
CM234A |
-
|
| Host |
Mouse |
| Klon |
XM26 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Reveal modified Citrate pH 6.0 |
| Positivkontrolle |
Normal prostate |
| Verdünnung |
1:25 |
| Isotyp |
Mouse IgG1 kappa |
| Lokalisation |
Cytoplasmic |
Cytokeratin 5 (CK5)
|
Biocare Medical |
XM26 |
1 ml |
Concentrate |
CE/IVD |
CM234C |
-
|
| Host |
Mouse |
| Klon |
XM26 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Reveal modified Citrate pH 6.0 |
| Positivkontrolle |
Normal prostate |
| Verdünnung |
- |
| Isotyp |
Mouse IgG1 kappa |
| Lokalisation |
Cytoplasmic |
Cytokeratin 5 (CK5)
|
Biocare Medical |
XM26 |
6 ml |
Ready-to-use |
CE/IVD |
PM234AA |
-
|
| Host |
Mouse |
| Klon |
XM26+LL002 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Skin |
| Verdünnung |
1:25 - 1:75 |
| Isotyp |
Mouse |
| Lokalisation |
Cytoplasm |
Cytokeratin 5 & 14
|
Diagnostic Biosystems |
XM26+LL002 |
1 ml |
Concentrate |
CE/IVD |
MOB433 |
-
|
| Host |
Mouse |
| Klon |
XM26+LL002 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Skin |
| Verdünnung |
1:25 - 1:75 |
| Isotyp |
Mouse |
| Lokalisation |
Cytoplasm |
Cytokeratin 5 & 14
|
Diagnostic Biosystems |
XM26+LL002 |
0.1 ml |
Concentrate |
CE/IVD |
MOB433-01 |
-
|
| Host |
Mouse |
| Klon |
XM26+LL002 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Skin |
| Verdünnung |
1:25 - 1:75 |
| Isotyp |
Mouse |
| Lokalisation |
Cytoplasm |
Cytokeratin 5 & 14
|
Diagnostic Biosystems |
XM26+LL002 |
0.5 ml |
Concentrate |
CE/IVD |
MOB433-05 |
-
|
| Host |
Mouse |
| Klon |
XM26+LL002 |
| Format |
Ready-to-use |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Skin |
| Verdünnung |
- |
| Isotyp |
Mouse |
| Lokalisation |
Cytoplasm |
Cytokeratin 5 & 14
|
Diagnostic Biosystems |
XM26+LL002 |
6 ml |
Ready-to-use |
CE/IVD |
PDM140 |
-
|
| Host |
Mouse |
| Klon |
XM26+BC4A4 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Reveal modified Citrate pH 6.0 |
| Positivkontrolle |
Normal breast, ductal cell carcinoma |
| Verdünnung |
- |
| Isotyp |
Mouse IgG1+IgG2a |
| Lokalisation |
Cytoplasmic and nuclear |
Cytokeratin 5 + p63
|
Biocare Medical |
XM26+BC4A4 |
6 ml |
Ready-to-use |
CE/IVD |
PM235AA |
-
|
| Host |
Mouse |
| Klon |
XM26+BC4A4 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Reveal modified Citrate pH 6.0 |
| Positivkontrolle |
Normal breast, ductal cell carcinoma |
| Verdünnung |
- |
| Isotyp |
Mouse IgG1+IgG2a |
| Lokalisation |
Cytoplasmic and nuclear |
Cytokeratin 5 + p63
|
Biocare Medical |
XM26+BC4A4 |
25 ml |
Ready-to-use |
CE/IVD |
PM235H |
-
|
| Host |
Mouse |
| Klon |
D5-16B4 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Mesothelioma, prostate. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Isolated Cytokeratin 5 |
| Lokalisation |
Cytoplasm |
Cytokeratin 5/6
|
Zeta Corporation |
D5-16B4 |
1.0 ml |
Concentrate |
CE/IVD |
Z2133ML |
-
|
| Host |
Mouse |
| Klon |
D5-16B4 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Mesothelioma, prostate. |
| Verdünnung |
- |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Isolated Cytokeratin 5 |
| Lokalisation |
Cytoplasm |
Cytokeratin 5/6
|
Zeta Corporation |
D5-16B4 |
7 ml |
Ready-to-use |
CE/IVD |
Z2133MP |
-
|
| Host |
Mouse |
| Klon |
D5-16B4 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Mesothelioma, prostate. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Isolated Cytokeratin 5 |
| Lokalisation |
Cytoplasm |
Cytokeratin 5/6
|
Zeta Corporation |
D5-16B4 |
0.5 ml |
Concentrate |
CE/IVD |
Z2133MS |
-
|
| Host |
Mouse |
| Klon |
D5-16B4 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Mesothelioma, prostate. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Isolated Cytokeratin 5 |
| Lokalisation |
Cytoplasm |
Cytokeratin 5/6
|
Zeta Corporation |
D5-16B4 |
0.1 ml |
Concentrate |
CE/IVD |
Z2133MT |
-
|
| Host |
Mouse |
| Klon |
CK5/6.007 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
EDTA o Citrate |
| Positivkontrolle |
Prostate or skin |
| Verdünnung |
1:100 |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
CK5/6 |
| Lokalisation |
Cytoplasmic |
Cytokeratin 5/6 (CK 5/6)
|
Biocare Medical |
CK5/6.007 |
0.1 ml |
Concentrate |
CE/IVD |
CM105C |
-
|
| Host |
Mouse+Rabbit |
| Klon |
XM26+LL002+4A4+BC1+EP30 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Breast cancer |
| Verdünnung |
- |
| Isotyp |
IgG1/kappa, IgG3, IgG2a/kappa, Rabbit IgG |
| Lokalisation |
Cytoplasmic and nuclear |
Cytokeratin 5/14 + p63 + Cytokeratin 7/18 (ADH-5)
|
Biocare Medical |
XM26+LL002+4A4+BC1+EP30 |
6 ml |
Ready-to-use |
CE/IVD |
PM360DSAA |
-
|
| Host |
Mouse+Rabbit |
| Klon |
XM26+LL002+4A4+BC1+EP30 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Breast cancer |
| Verdünnung |
- |
| Isotyp |
IgG1/kappa, IgG3, IgG2a/kappa, Rabbit IgG, |
| Lokalisation |
Cytoplasmic and nuclear |
Cytokeratin 5/14 + p63 + Cytokeratin 7/18 (ADH-5)
|
Biocare Medical |
XM26+LL002+4A4+BC1+EP30 |
25 ml |
Ready-to-use |
CE/IVD |
PM360DSH |
-
|
| Host |
Mouse+Rabbit |
| Klon |
XM26+LL002+4A4+polyclonal |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Prostate intraepithelial neoplasia PIN |
| Verdünnung |
- |
| Isotyp |
MouseIgG1/kappa+IgG3+IgG2a/kappa+not determined |
| Lokalisation |
Cytoplasmic and nuclear |
Cytokeratin 5/14 + p63 + P504S
|
Biocare Medical |
XM26+LL002+4A4+polyclonal |
6 ml |
Ready-to-use |
RUO |
PPM225DSAA |
-
|
| Host |
Mouse+Rabbit |
| Klon |
XM26+LL002+4A4+polyclonal |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Prostate intraepithelial neoplasia PIN |
| Verdünnung |
- |
| Isotyp |
MouseIgG1/kappa+IgG3+IgG2a/kappa+not determined |
| Lokalisation |
Cytoplasmic and nuclear |
Cytokeratin 5/14 + p63 + P504S
|
Biocare Medical |
XM26+LL002+4A4+polyclonal |
25 ml |
Ready-to-use |
RUO |
PPM225DSH |
-
|
| Host |
Rabbit |
| Klon |
BC1 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Ovarian cancer, breast cancer |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cytoplasmic |
Cytokeratin 7
|
Biocare Medical |
BC1 |
0.1 ml |
Concentrate |
CE/IVD |
CRM339A |
-
|
| Host |
Rabbit |
| Klon |
BC1 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Ovarian cancer, breast cancer |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cytoplasmic |
Cytokeratin 7
|
Biocare Medical |
BC1 |
1 ml |
Concentrate |
CE/IVD |
CRM339C |
-
|
| Host |
Rabbit |
| Klon |
BC1 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Ovarian cancer, breast cancer |
| Verdünnung |
- |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cytoplasmic |
Cytokeratin 7
|
Biocare Medical |
BC1 |
6 ml |
Ready-to-use |
CE/IVD |
PRM339AA |
-
|
| Host |
Mouse |
| Klon |
OV-TL-12:30 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Ovarian carcinoma. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
OTN II ovarian carcinoma cell line |
| Lokalisation |
Cytoplasm |
Cytokeratin 7
|
Zeta Corporation |
OV-TL-12:30 |
1ml |
Concentrate |
CE/IVD |
Z2067ML |
-
|
| Host |
Mouse |
| Klon |
OV-TL-12:30 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Ovarian carcinoma. |
| Verdünnung |
- |
| Isotyp |
IgG1 /κ |
| Verdünnung |
OTN II ovarian carcinoma cell line |
| Lokalisation |
Cytoplasm |
Cytokeratin 7
|
Zeta Corporation |
OV-TL-12:30 |
7 ml |
Ready-to-use |
CE/IVD |
Z2067MP |
-
|
| Host |
Mouse |
| Klon |
OV-TL-12:30 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Ovarian carcinoma. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
OTN II ovarian carcinoma cell line |
| Lokalisation |
Cytoplasm |
Cytokeratin 7
|
Zeta Corporation |
OV-TL-12:30 |
0.5 ml |
Concentrate |
CE/IVD |
Z2067MS |
-
|
| Host |
Mouse |
| Klon |
OV-TL-12:30 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Ovarian carcinoma. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
OTN II ovarian carcinoma cell line |
| Lokalisation |
Cytoplasm |
Cytokeratin 7
|
Zeta Corporation |
OV-TL-12:30 |
0.1 ml |
Concentrate |
CE/IVD |
Z2067MT |
-
|
| Host |
Mouse |
| Klon |
LP1K |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Fast Enzyme |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
IgG1 |
| Verdünnung |
Sonicated cytoskeleton fractions from SV40 transformed neonatal keratinocytes |
| Lokalisation |
Cytoplasm |
Cytokeratin 7 (LP1K)
|
Diagnostic Biosystems |
LP1K |
1 ml |
Concentrate |
CE/IVD |
MOB563 |
-
|
| Host |
Mouse |
| Klon |
LP1K |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Fast Enzyme |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
IgG1 |
| Verdünnung |
Sonicated cytoskeleton fractions from SV40 transformed neonatal keratinocytes |
| Lokalisation |
Cytoplasm |
Cytokeratin 7 (LP1K)
|
Diagnostic Biosystems |
LP1K |
0.1 ml |
Concentrate |
CE/IVD |
MOB563-01 |
-
|
| Host |
Mouse |
| Klon |
LP1K |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Fast Enzyme |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
IgG1 |
| Verdünnung |
Sonicated cytoskeleton fractions from SV40 transformed neonatal keratinocytes |
| Lokalisation |
Cytoplasm |
Cytokeratin 7 (LP1K)
|
Diagnostic Biosystems |
LP1K |
0.5 ml |
Concentrate |
CE/IVD |
MOB563-05 |
-
|
| Host |
Mouse |
| Klon |
LP1K |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Fast Enzyme |
| Positivkontrolle |
Tonsil |
| Verdünnung |
- |
| Isotyp |
IgG1 |
| Verdünnung |
Sonicated cytoskeleton fractions from SV40 transformed neonatal keratinocytes |
| Lokalisation |
Cytoplasm |
Cytokeratin 7 (LP1K)
|
Diagnostic Biosystems |
LP1K |
6 ml |
Ready-to-use |
CE/IVD |
PDM563 |
-
|
| Host |
Mouse |
| Klon |
LP1K |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Fast Enzyme |
| Positivkontrolle |
Tonsil |
| Verdünnung |
- |
| Isotyp |
IgG1 |
| Verdünnung |
Sonicated cytoskeleton fractions from SV40 transformed neonatal keratinocytes |
| Lokalisation |
Cytoplasm |
Cytokeratin 7 (LP1K)
|
Diagnostic Biosystems |
LP1K |
25 ml |
Ready-to-use |
CE/IVD |
PDM563-25 |
-
|
| Host |
Rabbit |
| Klon |
SP102 |
| Format |
Concentrate |
| Reaktivität |
BV, MS, PG, RT |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Breast ductal carcinoma |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide corresponding to C-terminus of human keratin 8 |
| Lokalisation |
Cytoplasm, Cell Membrane |
Cytokeratin 8
|
Zytomed Systems GmbH |
SP102 |
0.5 ml |
Concentrate |
RUO |
503-4022 |
-
|
| Host |
Rabbit |
| Klon |
SP102 |
| Format |
Concentrate |
| Reaktivität |
BV, MS, PG, RT |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Breast ductal carcinoma |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide corresponding to C-terminus of human keratin 8 |
| Lokalisation |
Cytoplasm, Cell Membrane |
Cytokeratin 8
|
Zytomed Systems GmbH |
SP102 |
1 ml |
Concentrate |
RUO |
503-4024 |
-
|
| Host |
Mouse |
| Klon |
35ßH11 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate, Pepsin or Fast Enzyme |
| Positivkontrolle |
Skin |
| Verdünnung |
1:10 - 1:25 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasm |
Cytokeratin 8
|
Diagnostic Biosystems |
35ßH11 |
1 ml |
Concentrate |
CE/IVD |
MOB054 |
-
|
| Host |
Mouse |
| Klon |
35ßH11 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate, Pepsin or Fast Enzyme |
| Positivkontrolle |
Skin |
| Verdünnung |
1:10 - 1:25 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasm |
Cytokeratin 8
|
Diagnostic Biosystems |
35ßH11 |
0.1 ml |
Concentrate |
CE/IVD |
MOB054-01 |
-
|
| Host |
Mouse |
| Klon |
35ßH11 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate, Pepsin or Fast Enzyme |
| Positivkontrolle |
Skin |
| Verdünnung |
1:10 - 1:25 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasm |
Cytokeratin 8
|
Diagnostic Biosystems |
35ßH11 |
0.5 ml |
Concentrate |
CE/IVD |
MOB054-05 |
-
|
| Host |
Mouse |
| Klon |
35ßH11 |
| Format |
Ready-to-use |
| Methode |
F, P |
| Vorbehandlung |
Citrate, Pepsin or Fast Enzyme |
| Positivkontrolle |
Skin |
| Verdünnung |
- |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasm |
Cytokeratin 8
|
Diagnostic Biosystems |
35ßH11 |
6 ml |
Ready-to-use |
CE/IVD |
PDM117 |
-
|
| Host |
Mouse |
| Klon |
ZM123 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Breast carcinoma. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Recombinant full-length human KRT8 protein |
| Lokalisation |
Cytoplasm |
Cytokeratin 8
|
Zeta Corporation |
ZM123 |
1.0 ml |
Concentrate |
CE/IVD |
Z2433ML |
-
|
| Host |
Mouse |
| Klon |
ZM123 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Breast carcinoma. |
| Verdünnung |
- |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Recombinant full-length human KRT8 protein |
| Lokalisation |
Cytoplasm |
Cytokeratin 8
|
Zeta Corporation |
ZM123 |
7 ml |
Ready-to-use |
CE/IVD |
Z2433MP |
-
|
| Host |
Mouse |
| Klon |
ZM123 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Breast carcinoma. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Recombinant full-length human KRT8 protein |
| Lokalisation |
Cytoplasm |
Cytokeratin 8
|
Zeta Corporation |
ZM123 |
0.5 ml |
Concentrate |
CE/IVD |
Z2433MS |
-
|
| Host |
Mouse |
| Klon |
ZM123 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Breast carcinoma. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Recombinant full-length human KRT8 protein |
| Lokalisation |
Cytoplasm |
Cytokeratin 8
|
Zeta Corporation |
ZM123 |
0.1 ml |
Concentrate |
CE/IVD |
Z2433MT |
-
|
| Host |
Rabbit |
| Klon |
EP7 + EP30 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Colon cancer |
| Verdünnung |
- |
| Isotyp |
IgG |
| Lokalisation |
Cytoplasm |
Cytokeratin 8 & 18
|
Biocare Medical |
EP7 + EP30 |
6 ml |
Ready-to-use |
CE/IVD |
API3161AA |
-
|
| Host |
Mouse |
| Klon |
5D3 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Pepsin or Trypsin |
| Positivkontrolle |
Skin |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasm |
Cytokeratin 8 & 18
|
Diagnostic Biosystems |
5D3 |
1 ml |
Concentrate |
CE/IVD |
MOB189 |
-
|
| Host |
Mouse |
| Klon |
5D3 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Pepsin or Trypsin |
| Positivkontrolle |
Skin |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasm |
Cytokeratin 8 & 18
|
Diagnostic Biosystems |
5D3 |
0.1 ml |
Concentrate |
CE/IVD |
MOB189-01 |
-
|
| Host |
Mouse |
| Klon |
5D3 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Pepsin or Trypsin |
| Positivkontrolle |
Skin |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasm |
Cytokeratin 8 & 18
|
Diagnostic Biosystems |
5D3 |
0.5 ml |
Concentrate |
CE/IVD |
MOB189-05 |
-
|
| Host |
Mouse |
| Klon |
IVT-2000 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate or Fast Enzyme |
| Verdünnung |
- |
| Isotyp |
Mouse IgG |
| Lokalisation |
Cytoplasm |
Cytokeratin 8 & 18
|
Zytomed Systems GmbH |
IVT-2000 |
6 ml |
Ready-to-use |
RUO |
MSG035 |
-
|
| Host |
Mouse |
| Klon |
IVT-2000 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate or Fast Enzyme |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
Mouse IgG |
| Lokalisation |
Cytoplasm |
Cytokeratin 8 & 18
|
Zytomed Systems GmbH |
IVT-2000 |
1 ml |
Concentrate |
RUO |
MSK035 |
-
|